Moderna's Ascentage Pharma Appoints New Directors to Enhance Oncology Innovation Strategy

Ascentage Pharma Strengthens Leadership with Strategic Appointments

Ascentage Pharma, a biopharmaceutical firm dedicated to addressing critical unmet medical needs in oncology, announces the strategic appointments of Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors, effective November 25, 2024. This move comes at a crucial time for Ascentage as the company aims to bolster its global innovation strategy and navigate an increasingly competitive landscape in the biopharmaceutical industry. Dr. Dajun Yang, the company's Chairman and CEO, expresses enthusiasm about the addition of these accomplished professionals, emphasizing their wealth of experience in finance, investment, and business development.

Ms. Bozilenko, currently serving as the President and CEO of Biothea Pharma, brings a robust financial background to the table. Her previous roles include significant positions at William Blair & Co., Bear Stearns, and Banc of America Securities, along with board memberships at various pharmaceutical companies, including Olema Pharmaceuticals and SynAct Pharma. With a bachelor’s degree in biochemistry and a master’s in social science from the University of Chicago, Ms. Bozilenko's expertise aligns well with Ascentage Pharma's focus on innovating within the oncology sector. Her insights are expected to enhance the company’s strategic direction, enabling it to capitalize on emerging market opportunities.

Dr. Yu complements this leadership enhancement with her extensive experience in both operational and investment roles. As the Chief Operating Officer at Panacea Venture, she has honed her skills in venture capital and business development. Her past leadership roles at LianBio and China Renaissance Securities further illustrate her capability to drive strategic initiatives. Dr. Yu's background also includes pivotal contributions at WuXi AppTec and Pfizer, where she led key ventures in the biopharmaceutical domain. Together, the appointments of Ms. Bozilenko and Dr. Yu signal Ascentage Pharma's commitment to leveraging diverse expertise to advance its mission in tackling significant challenges in the oncology treatment landscape.

In addition to these strategic appointments, Ascentage Pharma's focus on innovation is increasingly vital as the biopharmaceutical sector experiences rapid advancements. The insights provided by Ms. Bozilenko and Dr. Yu are anticipated to play a crucial role in guiding the company's research and development efforts, ultimately enhancing its product pipeline. Their combined expertise positions Ascentage to better navigate challenges and seize opportunities in a dynamic market.

The appointments reflect a broader trend in the biopharmaceutical industry, where companies seek to integrate diverse leadership to foster innovation and drive growth. As Ascentage Pharma prepares to embark on its next phase, the addition of these seasoned professionals underscores the company’s dedication to advancing healthcare solutions in oncology.